PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: Implication for Parkinson's disease

Journal of Molecular Neuroscience

Volumn 50, Issue 3, 2013, Pages 600-607

  Brown, Dwayne ^a   Tamas, Andrea ^b   Reglödi, Dora ^b   Tizabi, Yousef ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Apoptosis; BDNF; Neuroprotection; p CREB; PACAP; Salsolinol; SH SY5Y cell line

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 3; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; SALSOLINOL; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NERVE CELL NECROSIS; NEUROBLASTOMA CELL; NEUROPROTECTION; PARKINSON DISEASE; PREMEDICATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOPAMINERGIC NEURONS; HUMANS; ISOQUINOLINES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RECEPTORS, PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE;

MUS;

EID: 84878930078     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-013-0015-7     Document Type: Article

References (53)

1. Bitner S (2012) Cyclic AMP response element-binding protein (CREB) phosphorylation: a mechanistic marker in the development of memory enhancing Alzheimer's disease therapeutics. Biochem Pharmacol 83:705-714
2. Bollimuntha S, Ebadi M, Singh BB (2006) TRPC1 protects human SH-SY5Y cells against salsolinol-induced cytotoxicity by inhibiting apoptosis. Brain Res 1099:141-149
3. Botia B, Jolivel V, Burel D et al (2011) Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum. Neurotox Res 19:423-434
4. Copeland RL, Das JR, Kanaan YM (2007) Antiapoptotic effects of nicotine in its protection against salsolinol-induced cytotoxicity. Neurotox Res 12:61-69
5. Das JR, Tizabi Y (2009) Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res 16:194-204
6. Dejda A, Sokolowska P, Nowak JZ (2005) Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep 57:307-320
7. Dogrukol-Ak D, Kumar VB, Ryerse JS, Farr SA, Verma S, Nonaka N (2009) Isolation of peptide transport system-6 from brain endothelial cells: therapeutic effects with antisense inhibition in Alzheimer and stroke models. J Cereb Blood Flow Metab 29:411-422
8. Fernandez HH (2012) Updates in the medical management of Parkinson disease. Cleve Clin J Med 79:28-35
9. Frechilla D, Garcia-Osta A, Palacios S, Cenarruzabebeitia E, Del Rio J (2001) BDNF mediates the neuroprotective effect of PACAP-38 on rat cortical neurons. Neuroreport 12:919-923
10. Guillot TS, Richardson JR, Wang MZ et al (2008) PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides 42:423-434
11. Han BH, D'Costa A, Back SA et al (2000) BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Neurobiol Dis 7:38-53
12. Healy DG, Abou-Sleiman PM, Wood NW (2004) PINK, PANK, or PARK? A clinicians' guide to familial parkinsonism. Lancet Neurol 3:652-662
13. Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79:368-376
14. Jantas D, Pytel M, Mozrzymas JW et al (2008) The attenuating effect of memantine on staurosporine-, salsolinol- and doxorubicin-induced apoptosis in human neuroblastoma SH-SY5Y cells. Eurochem Int 52:864-877
15. Kim DH, Zhao X (2005) BDNF protects neurons following injury by modulation of caspase activity. Neurocrit Care 3:71-76
16. Lang AE (2009) When and how should treatment be started in Parkinson disease. Neurology 72:S39-S43
17. Lazarovici P, Cohen G, Arien-Zakay H et al (2012) Multimodal neuroprotection induced by PACAP38 in oxygen-glucose deprivation and middle cerebral artery occlusion stroke models. J Mol Neurosci 48:526-540
18. Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM (2004) Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol Cell Neurosci 25:536-547
19. Li N, Liu GT (2010) The novel squamosamide derivative FLZ enhances BDNF/TrkB/CREB signaling and inhibits neuronal apoptosis in APP/PS1 mice. Acta Pharmacol Sin 31:265-272
20. Maruyama W, Yi H, Takahashi T et al (2004) Neuroprotective function of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane, [R-(-)-BPAP], against apoptosis induced by N-methyl(R)salsolinol, an endogenous dopaminergic neurotoxin, in human dopaminergic neuroblastoma SH-SY5Y cells. Life Sci 75:107-117
21. Masuo Y, Ohtaki T, Masuda Y, Tsuda M, Fujino M (1992) Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections. Brain Res 575:113-123
22. Masuo Y, Suzuki N, Matsumoto H et al (1993) Regional distribution of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat central nervous system as determined by sandwich-enzyme immunoassay. Brain Res 602:657-663
23. Morris HR (2005) Genetics of Parkinson's disease. Ann Med 37:86-96
24. Nakamachi T, Tsuchida M, Kagami N et al (2012) IL-6 and PACAP receptor expression and localization after global brain ischemia in mice. J Mol Neurosci 48:518-525
25. Naoi M, Maruyama W, Nagy GM (2004) Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains. Neurotoxicology 25:193-204
26. Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I (2000) Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res 854:257-262
27. Priestley JV, Michael-Titus AT, Tetziaff W (2012) Limiting spinal cord injury by pharmacological intervention. Handb Clin Neurol 109:463-484
28. Puerta E, Hervias I, Barros-Minones L et al (2010) Sildenafil protects against 3-nitropropionic acid neurotoxicity through the modulation of calpain, CREB, and BDNF. Neurobiol Dis 38:237-245
29. Purves D, Augustine GJ, Fitzpatrick D, Hall WC, LaMantia A, White LE (2008) Neuroscience, 4th edn. Sinauer Associates, Sunderland, pp 170-176
30. Racz B, Tamas A, Kiss P et al (2006) Involvement of ERK and CREB signaling pathways in the protective effect of PACAP in monosodium glutamate-induced retinal lesion. Ann N Y Acad Sci 1070:507-511
31. Ramlochansingh C, Taylor RE, Tizabi Y (2011) Toxic effects of low alcohol and nicotine combinations in SH-SY5Y cells are apoptotically mediated. Neurotox Res 20:263-269
32. Rat D, Schmitt U, Tippmann F et al (2011) Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J 25:3208-3218
33. Reglödi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A (2000) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31:1411-1417
34. Reglödi D, Tamas A, Lubics A, Szalontay L, Lengvari I (2004) Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Regul Pept 123:85-94
35. Reglödi D, Tamas A, Lengvari I, Toth G, Szalontay L, Lubics A (2006) Comparative study on the effects of PACAP in young, aging, and castrated males in a rat model of Parkinson's disease. Ann NY Acad Sci 1070:518-524
36. Reglödi D, Kiss P, Lubics A, Tamas A (2011) Review on the protective effect of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 17:962-972
37. Reglödi D, Kiss P, Szabadfi K et al (2012) PACAP is an endogenous protective factor-insights from PACAP-deficient mice. J Mol Neurosci 48:482-492
38. Samii A, Nutt JG, Ransom BR (2004) Parkinson's disease. Lancet 363:1783-1793
39. Somogyvari-Vigh A, Reglödi D (2004) Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des 10:2861-2889
40. Sorimachi H, Mamitsuka H, Ono Y (2012) Understanding the substrate specificity of conventional calpains. Biol Chem 393:853-871
41. Storch A, Ott S, Hwang YI et al (2002) Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem Pharmacol 63:909-920
42. Suk K, Park JH, Lee WH (2004) Neuropeptide PACAP inhibits hypoxic activation of brain microglia: a protective mechanism against microglial neurotoxicity in ischemia. Brain Res 1026:151-156
43. Szabadfi K, Atlasz T, Kiss P et al (2012) Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox Res 21:41-48
44. Tamas A, Reglödi D, Farkas O et al (2012a) Effect of PACAP in central and peripheral nerve injuries. Int J Mol Sci 13:8430-8448
45. Tamas A, Szabadfi K, Nemeth A et al (2012b) Comparative examination of inner ear in wild type and pituitary adenylate cyclase activating polypeptide (PACAP)-deficient mice. Neurotox Res 21:435-444
46. Tsuchikawa D, Nakamachi T, Tsuchida M et al (2012) Neuroprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on spinal cord injury. J Mol Neurosci 48:508-517
47. Tuncel N, Korkmaz OT, Tekin N, Sener E, Akyuz F, Inal M (2012) Antioxidant and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. J Mol Neurosci 46:51-57
48. Vaudry D, Gonzalez BJ, Basille M et al (2000) The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells in mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32. Proc Natl Acad Sci USA 97:13390-13395
49. Vaudry D, Falluel-Morel A, Bougault S et al (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283-357
50. von Bohlen, Halbach O, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol 73:151-177
51. Wang G, Qi C, Fan GH, Zhou HY, Chen SD (2005) PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. FEBS Lett 579:4005-4011
52. Wang G, Pan J, Tan YY et al (2008) Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K (ATP) subunits and D2 receptors in the striatum. Neuropeptides 42:267-276
53. Yaka R, He DY, Phamluong K, Ron D (2003) Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-d-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem 278:9630-9963